ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.

Aug 31, 2024 - 04:00

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.

Read the original article

Tags:

Previous Article

J&J targets generalised myasthenia gravis landscape with nipocalimab

ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies

STAT+: Delfi launches its blood test to screen for lung...

Oct 10, 2023

Sanofi invests $1.4bn in insulin production in Germany

Sanofi invests $1.4bn in insulin production in Germany

Aug 3, 2024

Gilead Sciences reports net income rise in Q2 2024

Gilead Sciences reports net income rise in Q2 2024

Aug 11, 2024